Company: PTPI
Filing Date: 2025-02-14
Form Type: S-1/A
Source: 0001410578-25-000137
Chunk: 237

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-1/A
Chunk 237
---
 Prescription 
 Medications  |          ​ | ​ 
 ​ | ​               
 ​               
 Medical Devices |         ​ 
         ​ | ​ 
 ​ | ​            
 ​            
 Consolidated |          ​ 
          ​ |
|:-----------------------|:--|:-------------|-----------:|:--|:----------------|----------:|:--|:-------------|-----------:|
| Intangible assets, net | ​ | $            |  7,178,704 | ​ | $               | 5,065,780 | ​ | $            | 12,244,484 |
| Total segment assets   | ​ | $            | 25,831,048 | ​ | $               | 6,590,166 | ​ | $            | 32,421,214 |

19) Private Placement On July 13, 2023, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which we agreed to sell in a private placement to the Investors (i) an aggregate of 15,000shares of our newly-designated Series A Convertible Preferred Stock, with a par value of $ 0.0001per share and a stated value of $ 1,000per share (the “Series A Preferred Stock”), initially convertible into up to 6,666,668shares of our common stock, par value $ 0.0001per share (the “Common Stock”) at an initial conversion price of $ 2.25per share (the “Series A Preferred Shares”), and (ii) warrants to acquire up to an aggregate of 6,666,668shares of Common Stock (the “Warrants”) at an initial exercise price of $ 2.25per share (collectively, the “Private Placement”). Pursuant to the terms of the Certificate of Designations of Series A Convertible Preferred Stock (the “Certificate of Designations”) and the Warrants, each of the Conversion Price (as defined below) and the exercise price and the number of shares underlying the Warrants is subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment in the event of any issuances of Common Stock, or securities convertible, exercisable or exchangeable for Common Stock, at a price below the then-applicable Conversion Price (subject to certain exceptions). As of December 31, 2023, the Conversion Price and the exercise price of the Warrants was